Aurinia Pharmaceuticals Inc. AUPH
Institutional shares held
55.6 Million
838K
calls
1.18M
puts
Total value of holdings
$310M
$4.67M
calls
$6.58M
puts
Market Cap
$790M
141,892,000
Shares Out.
Institutional ownership
39.21%
# of Institutions
205
We take great care to ensure that the data presented and summarized in this overview for Aurinia Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AUPH
View all-
Armistice Capital, LLC New York, NY12.3MShares$68.3 Million0.84% of portfolio
-
Black Rock Inc. New York, NY8.66MShares$48.3 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$22.1 Million1.4% of portfolio
-
State Street Corp Boston, MA2.77MShares$15.4 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.15MShares$12 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL2.06MShares$11.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.05MShares$11.4 Million1.25% of portfolio
-
Geode Capital Management, LLC Boston, MA1.6MShares$8.93 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.53MShares$8.53 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.3MShares$7.26 Million0.0% of portfolio
Latest Institutional Activity in AUPH
Top Purchases
Top Sells
About AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Transactions at AUPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 21
2024
|
Brinda Balakrishnan Director |
SELL
Open market or private sale
|
Direct |
520
-2.88%
|
$2,600
$5.74 P/Share
|
|
May 21
2024
|
Jill Leversage Director |
SELL
Open market or private sale
|
Direct |
5,610
-30.28%
|
$28,050
$5.74 P/Share
|
|
May 21
2024
|
David R.W. Jayne Director |
SELL
Open market or private sale
|
Direct |
4,946
-10.03%
|
$24,730
$5.74 P/Share
|
|
May 21
2024
|
Daniel Billen Director |
SELL
Open market or private sale
|
Direct |
5,252
-15.73%
|
$26,260
$5.74 P/Share
|
|
May 21
2024
|
R. Hector Mac Kay Dunn Director |
SELL
Open market or private sale
|
Direct |
5,630
-23.24%
|
$28,150
$5.74 P/Share
|
|
Mar 06
2024
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
34,811
-6.56%
|
$174,055
$5.6 P/Share
|
|
Mar 06
2024
|
Peter Greenleaf Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
126,981
-7.7%
|
$634,905
$5.6 P/Share
|
|
Mar 06
2024
|
Stephen P. Robertson EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
57,745
-11.51%
|
$288,725
$5.6 P/Share
|
|
Mar 06
2024
|
Scott Michael Habig Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,777
-3.61%
|
$88,885
$5.6 P/Share
|
|
Mar 06
2024
|
Matthew Maxwell Donley EVP, Ops & Strategy |
SELL
Open market or private sale
|
Direct |
40,665
-6.51%
|
$203,325
$5.51 P/Share
|
|
Feb 27
2024
|
Volker Knappertz EVP, Research and Development |
SELL
Open market or private sale
|
Direct |
4,930
-1.52%
|
$29,580
$6.1 P/Share
|
|
Feb 20
2024
|
Volker Knappertz EVP, Research and Development |
SELL
Open market or private sale
|
Direct |
25,146
-7.2%
|
$125,730
$5.48 P/Share
|
|
Feb 20
2024
|
Matthew Maxwell Donley EVP, Ops & Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
216,666
+25.75%
|
-
|
|
Feb 20
2024
|
Scott Michael Habig Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,867
-3.12%
|
$79,335
$5.48 P/Share
|
|
Feb 20
2024
|
Scott Michael Habig Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
195,512
+27.78%
|
-
|
|
Feb 20
2024
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
661,538
+28.63%
|
-
|
|
Feb 20
2024
|
Joseph M Miller Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
196,153
+26.99%
|
-
|
|
Feb 20
2024
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
194,230
+27.91%
|
-
|
|
May 23
2023
|
David R.W. Jayne Director |
SELL
Open market or private sale
|
Direct |
8,733
-15.05%
|
$96,063
$11.26 P/Share
|
|
May 23
2023
|
Jill Leversage Director |
SELL
Open market or private sale
|
Direct |
4,815
-20.63%
|
$52,965
$11.26 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.46M
Shares
From
5
Insiders
| Grant, award, or other acquisition | 1.46M shares |
|---|
Sell / Disposition
346K
Shares
From
11
Insiders
| Open market or private sale | 346K shares |
|---|